Verona Pharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Rhea-AI Summary

Verona Pharma (NASDAQ: VRNA) announced that Ohtuvayre (ensifentrine) is now available in the US for COPD maintenance treatment. Key highlights:

- Over 2,000 HCP visits conducted and 100+ unique HCPs have prescribed Ohtuvayre
- Submitted IND for ensifentrine-glycopyrrolate combination therapy
- Plans to initiate Phase 2 trial for non-cystic fibrosis bronchiectasis in Q3 2024
- Cash position of $404.6 million as of June 30, 2024
- Q2 2024 R&D expenses increased to $19.4 million (Q2 2023: -$2.5 million)
- Q2 2024 SG&A expenses rose to $49.0 million (Q2 2023: $12.4 million)
- Q2 2024 net loss of $70.8 million (Q2 2023: $8.8 million loss)

The company believes its current cash position will fund operations beyond 2026, including Ohtuvayre's US commercial launch.

Positive

• Ohtuvayre (ensifentrine) now available in US for COPD maintenance treatment
• Over 100 unique HCPs have prescribed Ohtuvayre through specialty pharmacies
• Strong cash position of $404.6 million as of June 30, 2024
• Current cash expected to fund operations beyond 2026, including Ohtuvayre's US launch

Negative

• Q2 2024 net loss increased to $70.8 million from $8.8 million in Q2 2023
• R&D expenses rose to $19.4 million in Q2 2024 from -$2.5 million in Q2 2023
• SG&A expenses increased to $49.0 million in Q2 2024 from $12.4 million in Q2 2023

Financial Analyst

Verona Pharma's Q2 2024 results reveal significant progress but also substantial financial impacts from the launch of Ohtuvayre. Revenue generation has not yet begun, while expenses have increased dramatically. R&D expenses rose to $19.4 million from a net reversal last year, driven by milestone payments and pre-launch inventory costs. SG&A expenses surged to $49 million, up 295% year-over-year, primarily due to commercial launch activities and team expansion.

The net loss widened to $70.8 million, a substantial increase from $8.8 million in Q2 2023. However, the company's cash position remains strong at $404.6 million, bolstered by recent financing activities. This should provide runway beyond 2026, supporting the Ohtuvayre launch and pipeline development.

While the increased spending is expected for a product launch, investors should monitor the pace of Ohtuvayre adoption and future revenue generation to assess the return on this significant investment.

Medical Research Analyst

The FDA approval and launch of Ohtuvayre (ensifentrine) marks a significant milestone for COPD treatment, being the first novel inhaled product in over 20 years. Its dual bronchodilator and anti-inflammatory properties could potentially redefine COPD management. The initial reception seems positive, with over 100 unique HCPs prescribing Ohtuvayre in the early stages of launch.

Verona's pipeline expansion is also noteworthy. The IND submission for a fixed-dose combination of ensifentrine and glycopyrrolate could lead to a more convenient treatment option for COPD patients. Additionally, the planned Phase 2 trial for non-cystic fibrosis bronchiectasis (NCFBE) demonstrates the company's efforts to broaden ensifentrine's applications.

The upcoming presentations at major respiratory conferences will be important for further validating Ohtuvayre's efficacy and safety profile, potentially influencing its adoption rate among healthcare professionals.

Market Research Analyst

Verona Pharma's launch of Ohtuvayre enters a competitive COPD market, dominated by established players. However, being the first novel inhaled treatment in two decades gives it a unique selling proposition. The early traction with over 2,000 HCP visits and 100+ prescribers is encouraging, but sustained growth will be critical.

The company's commercial strategy, including the establishment of a specialty pharmacy network and pursuit of a product-specific J-code, demonstrates a well-thought-out approach to market penetration. The expected J-code in January 2025 could significantly improve reimbursement processes, potentially accelerating adoption.

Investors should closely monitor key performance indicators in the coming quarters, such as prescription growth rates, market share gains and progress in payer coverage. The COPD market is substantial, but Ohtuvayre's success will depend on effectively differentiating itself from existing treatments and overcoming potential barriers to adoption.

Ohtuvayre^TM (ensifentrine) now available; patient shipments started

Strong balance sheet supports commercialization and pipeline expansion

Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST

LONDON and RALEIGH, N.C., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a biopharmaceutical company focused on respiratory diseases, announces its financial results for the second quarter ended June 30, 2024, and provides a corporate update.

“We are very pleased today to announce that Ohtuvayre (ensifentrine) is now available in the US for the maintenance treatment of chronic obstructive pulmonary disease ("COPD") in adults,” said David Zaccardelli, Pharm. D., President and Chief Executive Officer. “Ohtuvayre is the first novel inhaled product available for the treatment of COPD in more than 20 years. Healthcare professionals ("HCPs") and patients are excited about Ohtuvayre’s potential to relieve COPD symptoms and we believe its bronchodilator and non-steroidal anti-inflammatory activity will redefine the treatment paradigm for COPD.

“Our field sales force began interacting with HCPs in late July and, to date, we have conducted over 2,000 HCP visits and more than 100 unique HCPs have prescribed Ohtuvayre through our exclusive network of specialty pharmacies. We are confident in the launch of Ohtuvayre and look forward to updating you on our progress.”

Program Updates and Key Milestones

The Company’s near-term milestones include:

• In July 2024, the Company submitted an investigational new drug application (“IND”) to the FDA to allow initiation of the clinical program for development of a fixed-dose combination of ensifentrine and glycopyrrolate, a long-acting muscarinic antagonist (“LAMA”), for the maintenance treatment of COPD via a nebulizer. Subject to clearance of the IND, the Company intends to initiate a Phase 2 dose-ranging trial in the third quarter of 2024.
• Also in the third quarter of 2024, the Company plans to initiate a Phase 2 clinical trial to assess the efficacy and safety of nebulized ensifentrine in patients with non-cystic fibrosis bronchiectasis (“NCFBE”).
• In the second half of 2024, the Company plans to present further analyses from the Phase 3 ENHANCE trials at the European Respiratory Society International Congress 2024 and at CHEST Annual Meeting 2024.
  

Second Quarter Highlights

• On June 26, 2024, the FDA approved Ohtuvayre (ensifentrine) for the maintenance treatment of COPD and the product is now available in the US.
• In June 2024, the Company submitted the J-code application and local coverage determination documents to support the launch and expects to receive a permanent, product-specific J-code for Ohtuvayre effective January 2025.
• In May 2024, the Company refinanced its $400 million debt facility and entered into a $250 million capped revenue interest purchase and sales agreement (“RIPSA”) with Oaktree Capital and OMERS Life Sciences (collectively the “$650 million strategic financing”).
• Also in May 2024, the Company presented eight posters including two oral presentations, at the American Thoracic Society International Conference (“ATS”) 2024. The posters highlighted additional pooled analyses of the Phase 3 ENHANCE trials with ensifentrine for the treatment of COPD. The abstracts are published on the ATS website and in the American Journal of Respiratory and Critical Care Medicine.

Second Quarter 2024 Financial Results

• Cash position: Cash and cash equivalents at June 30, 2024 were $404.6 million (December 31, 2023: $271.8 million). Following the approval of Ohtuvayre, the Company drew $70 million under the debt facility and $100 million under the RIPSA leading to the $404.6 million cash balance. The Company believes cash and cash equivalents at June 30, 2024, along with the funding expected to become available under the $650 million strategic financings will enable Verona Pharma to fund planned operating expenses and capital expenditure requirements beyond 2026 including the commercial launch of Ohtuvayre in the US.
• R&D Expenses: Research and development (“R&D”) expenses were $19.4 million for the second quarter ended June 30, 2024 (Q2 2023: a net reversal of costs of $2.5 million). This increase of $21.9 million was primarily driven by the accrual of the $6.3 million approval milestone due to Ligand, $2.5 million increase in share-based compensation largely driven by the recognition of performance restricted stock units (“PRSU”) expense and $1.7 million of expense related to pre-launch inventory production. Further, we had $2.5 million in clinical trial and other development costs in the three months ended June 30, 2024 while in the three months ended June 30, 2023, we recorded a reversal of costs of $6.3 million related to the resolution of a supplier matter, which resulted in net negative research and development expense for the three months ended June 30, 2023.
• SG&A Expenses: Selling general and administrative expenses (“SG&A”) were $49.0 million for the second quarter ended June 30, 2024 (Q2 2023: $12.4 million). This increase of $36.6 million was driven primarily by an accrual of the $15.0 million first sale milestone payment due to Ligand, an increase of $7.4 million for marketing and other commercial launch related activities and an increase of $2.3 million in other support costs including travel, professional and consulting fees and information technology costs. Additionally, share-based compensation increased by $8.0 million largely driven by the recognition of PRSU expense as well as an increase of $4.3 million in people-related costs as we built out our commercial organization including much of the field sales team.

• Net loss: Net loss was $70.8 million for the second quarter ended June 30, 2024 (Q2 2023: net loss $8.8 million).

Conference Call and Webcast Information
Verona Pharma will host an investment community webcast and conference call at 9:00 a.m. EDT / 2:00 p.m. BST on Thursday, August 8, 2024, to discuss the second quarter 2024 financial results and the corporate update.

To participate, please dial one of the following numbers and ask to join the Verona Pharma call:

• +1-833-816-1396 for callers in the United States
• +1-412-317-0489 for international callers

A live webcast will be available on the Events and Presentations link on the Investors page of the Company's website, www.veronapharma.com, and the audio replay will be available for 90 days. An electronic copy of the second quarter 2024 results press release will also be made available today on the Company’s website.

For further information please contact:

Verona Pharma plc	Tel: +1-844-341-9901
Victoria Stewart, Senior Director of Investor Relations and Communications	IR@veronapharma.com
Argot Partners US Investor Enquiries	Tel: +1-212-600-1902 verona@argotpartners.com
Ten Bridge Communications International / US Media Enquiries	Tel: +1-312-523-5016 tbcverona@tenbridgecommunications.com
Leslie Humbel

About Verona Pharma

Verona Pharma is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of chronic respiratory diseases with significant unmet medical needs. Ohtuvayre^TM (ensifentrine) is the Company’s first commercial product and the first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule. Ensifentrine has potential applications in non-cystic fibrosis bronchiectasis, cystic fibrosis, asthma and other respiratory diseases. For more information, please visit www.veronapharma.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical fact should be considered forward-looking statements. Words such as “anticipate,” “believe,” “plan,” “expect,” “intend,” “may,” “potential,” “prepare,” “possible” and similar words and expressions are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the potential benefits, efficacy and commercial strategy for Ohtuvayre, including, but not limited to, statements relating to the potential to change the treatment paradigm for adult COPD patients, the Company’s ability to successfully market and sell Ohtuvayre, the timing of the Company’s Phase 2 trial for the development of a fixed-dose combination of ensifentrine and glycopyrrolate for the maintenance treatment of COPD via delivery in a nebulizer and the Phase 2 clinical trial to assess the efficacy and safety of nebulized ensifentrine in patients with non-cystic fibrosis bronchiectasis, the potential applications of ensifentrine, the Company’s participation in upcoming events and presentations, and the Company’s cash runway.

These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from our expectations expressed or implied by the forward-looking statements, including, but not limited to, the following: our limited operating history; our need for additional funding to complete development and commercialization of Ohtuvayre which may not be available and which may force us to delay, reduce or eliminate our development or commercialization efforts; our reliance on the success of Ohtuvayre, our only commercial product; our reliance on third-party manufacturers and suppliers; the efficacy of Ohtuvayre compared to competing drugs; our ability to successfully commercialize Ohtuvayre; serious adverse, undesirable or unacceptable side effects associated with Ohtuvayre which could adversely affect our ability to commercialize Ohtuvayre; failure to develop Ohtuvayre for additional indications, alternate delivery methods, or as a combination therapy; failure to obtain approval for and commercialize Ohtuvayre in multiple major pharmaceutical markets; our commercial capabilities and infrastructure, including sales, marketing, operations, distribution, and reimbursement infrastructure, may not be adequate to successfully commercialize Ohtuvayre; lawsuits related to patents covering Ohtuvayre and the potential for our patents to be found invalid or unenforceable; lawsuits related to our licensing of patents and know-how from third parties for the commercialization of Ohtuvayre; changes in our tax rates, unavailability of certain tax credits or reliefs or exposure to additional tax liabilities or assessments that could affect our profitability, and audits by tax authorities that could result in additional tax payments for prior periods; the terms of our credit agreement and the revenue interest purchase and sale agreement ("RIPSA”) place restrictions on our operating and financial flexibility, and if we fail to comply with certain covenants in the RIPSA, our results of operations and financial condition may be harmed; and our vulnerability to natural disasters, global economic factors, geo-political actions and unexpected events, including health epidemics or pandemics. These and other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q for the period ended June 30, 2024 filed with the Securities and Exchange Commission (“SEC”) on August 8, 2024, and our other reports filed with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change, except as required under applicable law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Verona Pharma plc Consolidated Financial Summary (unaudited) (in thousands, except share and per share amounts)
		Three months ended June 30,
			2024				2023
Operating expenses
Research and development		$	19,388			$	(2,474	)
Selling, general and administrative			49,035				12,439
Total operating expenses			68,423				9,965
Operating loss			(68,423	)			(9,965	)
Other income/(expense)
Research and development tax credit			847				(1,934	)
Loss on extinguishment of debt			(3,653	)			-
Interest income			3,140				3,402
Interest expense			(1,757	)			(740	)
Foreign exchange gain			25				740
Total other (expense)/income, net			(1,398	)			1,468
Loss before income taxes			(69,821	)			(8,497	)
Income tax expense			(1,014	)			(310	)
Net loss		$	(70,835	)		$	(8,807	)
Weighted-average shares outstanding – basic and diluted			648,217,411				634,469,423
Loss per ordinary share – basic and diluted		$	(0.11	)		$	(0.01	)
		Jun-30				Mar-31
			2024				2024
Cash and cash equivalents		$	404,599			$	254,882
Total assets		$	434,123			$	289,912
Shareholders’ equity		$	168,274			$	224,988

FAQ

What is Verona Pharma's (VRNA) newly approved COPD treatment called?

Verona Pharma's newly approved COPD treatment is called Ohtuvayre (ensifentrine). It is now available in the US for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adults.

How many healthcare professionals have prescribed Ohtuvayre for Verona Pharma (VRNA) as of Q2 2024?

As of Q2 2024, more than 100 unique healthcare professionals (HCPs) have prescribed Ohtuvayre through Verona Pharma's exclusive network of specialty pharmacies.

What was Verona Pharma's (VRNA) cash position at the end of Q2 2024?

Verona Pharma's cash and cash equivalents at June 30, 2024, were $404.6 million, compared to $271.8 million on December 31, 2023.

What was Verona Pharma's (VRNA) net loss for Q2 2024?

Verona Pharma reported a net loss of $70.8 million for the second quarter ended June 30, 2024, compared to a net loss of $8.8 million in Q2 2023.